Update on the use of long-acting growth hormone in children.
Curr Opin Pediatr
; 36(4): 437-441, 2024 Aug 01.
Article
en En
| MEDLINE
| ID: mdl-38747211
ABSTRACT
PURPOSE OF REVIEW After extensive research and many years of waiting, long-acting growth hormone (LAGH) formulations have finally become a reality in clinical practice and emerge as a potential solution to address the challenges of daily injections of recombinant human GH (rhGH). In this review, we present a brief history of the development of LAGH and provide a critical analysis of the existing literature on the five LAGH available and approved to date for treatment in children. RECENT FINDINGS:
In clinical trials, LAGH therapy has shown noninferiority compared with daily rhGH therapy in promoting linear growth in children with GH deficiency, with similar rates of adverse events.SUMMARY:
In the real world, many questions still need to be answered, such as whether a specific group of patients will benefit most from the weekly injection, whether compliance will be better compared with daily rhGH, whether long-term efficacy, monitoring and safety profile will be the same for the different LAGH compounds, and whether the cost-effectiveness will justify their use in different settings.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hormona de Crecimiento Humana
/
Preparaciones de Acción Retardada
/
Trastornos del Crecimiento
Límite:
Child
/
Humans
Idioma:
En
Revista:
Curr Opin Pediatr
Asunto de la revista:
PEDIATRIA
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos